Novartis has discontinued a Phase III clinical trial programme of investigational lung cancer treatment ASA404 (vadimezan), following interim study results that indicated the drug was not likely to meet the trial’s primary endpoint.
The Phase III trial evaluated ASA404 in combination with chemotherapy as second-line treatment for patients with non-small cell lung cancer, with a primary endpoint to prolong overall survival.
An independent data monitoring committee recommended the discontinuation of the trial, and the company has notified the study investigators and regulatory agencies of the decision.
Novartis has said that the resources will be reallocated to other compounds in its oncology pipeline.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData